VYST - Institutional Analyst Inc. Initiates Covera
Post# of 1208
Roland Rick Perry, Editor of Biotech Stock Review, stated, “Now that the process has been perfected, Vystar has a viable ‘Intel Inside’ business model whereby established producers of natural latex can create and sell cleaner, better latex which, most importantly, can be done with their existing processing equipment with minor modifications and processing costs associated with the Vytex deproteinization kit and licensing...They can instead work with established producers who can now offer their end purchasers a better latex and simultaneously expand natural latex into markets which, until now, were hampered due to allergy concerns – the best example being medical gloves.”
https://www.vytex.com/blog/institutional-anal...age-vytex/
VYST